Sunday, September 6, 2026

Brazilian Fintechs Deploy AI Credit Models to Add 7M Clients While Holding Risk Margins Stable

Nu Holdings and Inter & Co deployed AI-driven underwriting systems in 2025 that enabled rapid client growth without degrading credit performance. Nu's nuFormer model powered 100+ product launches while maintaining stable risk-adjusted margins. Inter added 7 million clients—its best year—with newer cohorts transacting faster than predecessors.

Brazilian Fintechs Deploy AI Credit Models to Add 7M Clients While Holding Risk Margins Stable
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Nu Holdings put its nuFormer AI model into production in 2025 and launched over 100 products and features across its Latin American markets while keeping risk-adjusted net interest margins stable quarter-over-quarter. The deployment demonstrates how machine learning models can accelerate product velocity without sacrificing underwriting quality.

Inter & Co welcomed 7 million new clients in 2025, marking its strongest annual performance. The fintech maintains industry-leading funding costs at 65.6% of Brazil's CDI benchmark rate. Newer client cohorts are transacting faster and more frequently than older ones, indicating improved targeting from automated credit decisioning.

The AI models handle real-time portfolio monitoring alongside automated underwriting. Traditional banks process credit applications in days using manual review processes. AI systems evaluate hundreds of data points in seconds, including transaction patterns, payment histories, and behavioral signals invisible to rule-based systems.

Brazilian fintechs face unique credit risk challenges. The country's CDI rate fluctuates significantly, compressing margins during rate spikes. AI models adjust credit lines and pricing dynamically as portfolio conditions shift, maintaining profitability across rate cycles.

Nu's stable risk-adjusted margins despite rapid expansion suggest the nuFormer model identifies creditworthy clients more accurately than previous methods. The company avoided the common tradeoff between growth speed and credit quality that plagued earlier fintech lending waves.

Inter's accelerating cohort performance reveals another AI advantage. Newer clients transact more because better targeting matches products to customer needs upfront. Manual underwriting relies on demographic proxies; machine learning identifies behavioral patterns that predict product usage.

The 2025 results contrast with 2021-2022, when Brazilian fintechs expanded rapidly but suffered rising non-performing loans. AI models trained on post-pandemic data captured changing payment behaviors that rule-based systems missed.

Client acquisition costs declined as AI improved approval rates for qualified applicants while rejecting riskier profiles. Fewer false negatives mean less marketing waste; fewer false positives reduce collection expenses.

Both companies now iterate credit models continuously. Nu launched 100+ features by testing algorithms on live portfolios and rolling out improvements monthly rather than in annual cycles. This cadence was impossible under manual underwriting governance.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com